Beranda › Neoplasma Mieloproliferatif › Oklahoma › Oklahoma City
Uji klinis Neoplasma Mieloproliferatif di Oklahoma City, OK
4 studi untuk Neoplasma Mieloproliferatif mencari peserta di lokasi sekitar Oklahoma City (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Menerima pesertaFase 2
- University of Oklahoma Health Sciences Center, Oklahoma City
A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)
Menerima pesertaFase 2
- University of Oklahoma Health Sciences Center, Oklahoma City
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
Menerima pesertaFase 2
- University of Oklahoma Health Sciences Center, Oklahoma City
Project: Every Child for Younger Patients With Cancer
Menerima pesertaStudi observasional
- University of Oklahoma Health Sciences Center, Oklahoma City
Uji klinis Neoplasma Mieloproliferatif di kota lain
- Houston, TX16 studi
- New York City, NY15 studi
- Boston, MA14 studi
- Milwaukee, WI10 studi
- Miami, FL10 studi
- Durham, NC9 studi
- Baldwin Park, CA9 studi
- Seattle, WA9 studi
- Chicago, IL9 studi
- Portland, OR8 studi
- Cleveland, OH8 studi
- Atlanta, GA8 studi
Studi lain di Oklahoma City
- Kanker Paru Non-Sel Kecil28 studi
- Kanker Ovarium28 studi
- Kanker Endometrium25 studi
- Kanker Kolorektal22 studi
- Kanker Prostat21 studi
- Kanker Paru19 studi
- Kanker Payudara17 studi
- Kanker Metastatik16 studi
- Kanker (semua jenis)14 studi
- Leukemia Mieloid Akut14 studi
- Karsinoma Sel Skuamosa Kepala dan Leher13 studi
- Kanker Kandung Kemih11 studi
Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.